Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
NDC API
0
VMF
0
Canada
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Centrax
2. Demetrin
3. Lysanxia
4. Mono Demetrin
5. Reapam
1. Demetrin
2. Lysanxia
3. Centrax
4. Trepidan
5. Verstran
6. 2955-38-6
7. Prazepamum [inn-latin]
8. W 4020
9. K-373
10. Prazepam Civ
11. 2h-1,4-benzodiazepin-2-one, 7-chloro-1-(cyclopropylmethyl)-1,3-dihydro-5-phenyl-
12. Nsc 277179
13. 7-chloro-1-(cyclopropylmethyl)-5-phenyl-3h-1,4-benzodiazepin-2-one
14. 7-chloro-1-(cyclopropylmethyl)-1,3-dihydro-5-phenyl-2h-1,4-benzodiazepin-2-one
15. W-4020
16. Nsc-277179
17. 7-chloro-1-cyclopropylmethyl-5-phenyl-1h-1,4-benzodiazepin-2(3h)-one
18. Chebi:8362
19. Q30vcc064m
20. Prazene
21. Sedapran
22. 7-chloro-1-(cyclopropylmethyl)-5-phenyl-1,3-dihydro-2h-1,4-benzodiazepin-2-one
23. Ncgc00168256-01
24. Prazeene
25. Prazepamum
26. Settima
27. Dsstox_cid_1181
28. 2h-1,4-benzodiazepin-2-one, 1,3-dihydro-7-chloro-1-(cyclopropylmethyl)-5-phenyl-
29. Dsstox_rid_75994
30. Dsstox_gsid_21181
31. 7-chloro-1-(cyclopropylmethyl)-5-phenyl-2,3-dihydro-1h-1,4-benzodiazepin-2-one
32. Centrax (tn)
33. Cas-2955-38-6
34. Einecs 220-975-8
35. Brn 0895797
36. Unii-q30vcc064m
37. Dea No. 2764
38. Prazepam [usan:usp:inn:ban:jan]
39. Prazepam [iarc]
40. Prazepam [usan]
41. Prazepam [inn]
42. Prazepam [jan]
43. Prazepam [mi]
44. Prazepam [vandf]
45. Prazepam [mart.]
46. Chembl969
47. Prazepam [who-dd]
48. Schembl78272
49. Mls003899231
50. Prazepam [orange Book]
51. Prazepam Civ [usp-rs]
52. Gtpl7275
53. Prazepam (jp17/usan/inn)
54. Zinc1971
55. Prazepam [ep Monograph]
56. Dtxsid4021181
57. Prazepam 0.1 Mg/ml In Methanol
58. Prazepam 1.0 Mg/ml In Methanol
59. Tox21_112615
60. Tox21_200076
61. Nsc277179
62. Prazepam 1000 Microg/ml In Methanol
63. Db01588
64. Ncgc00168256-02
65. Ncgc00257630-01
66. Smr000058725
67. Db-047601
68. C07366
69. D00470
70. Wln: T67 Gnv Jn Ihj Cg Kr& G1- Al3tj
71. Q2149443
72. 7-chloro-1-(cyclopropylmethyl)-1,4-benzodiazepin-2-one
73. Prazepam, European Pharmacopoeia (ep) Reference Standard
74. 2h-1, 1,3-dihydro-7-chloro-1-(cyclopropylmethyl)-5-phenyl-
75. 2h-1, 7-chloro-1-(cyclopropylmethyl)-1,3-dihydro-5-phenyl-
76. Prazepam, United States Pharmacopeia (usp) Reference Standard
77. 7-chloro-1-(cyclopropylmethyl)-5-phenyl-1,3-dihydro-2h-1,4-benzodiazepin-2-one #
78. Prazepam Solution, 1.0 Mg/ml In Methanol, Ampule Of 1 Ml, Certified Reference Material
Molecular Weight | 324.8 g/mol |
---|---|
Molecular Formula | C19H17ClN2O |
XLogP3 | 3.6 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 3 |
Exact Mass | 324.1029409 g/mol |
Monoisotopic Mass | 324.1029409 g/mol |
Topological Polar Surface Area | 32.7 Ų |
Heavy Atom Count | 23 |
Formal Charge | 0 |
Complexity | 482 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
For the treatment of anxiety disorders.
Prazepam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant activity. Benzodiazepines may be habit-forming (causing mental or physical dependence), especially when taken for a long time or in high doses.
Anti-Anxiety Agents
Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)
GABA Modulators
Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here. (See all compounds classified as GABA Modulators.)
N05BA11
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
N - Nervous system
N05 - Psycholeptics
N05B - Anxiolytics
N05BA - Benzodiazepine derivatives
N05BA11 - Prazepam
Hepatic.
36-200 hours
Prazepam is believed to stimulate GABA receptors in the ascending reticular activating system. Since GABA is inhibitory, receptor stimulation increases inhibition and blocks both cortical and limbic arousal following stimulation of the brain stem reticular formation.
Global Sales Information
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
33
PharmaCompass offers a list of Prazepam API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Prazepam manufacturer or Prazepam supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Prazepam manufacturer or Prazepam supplier.
PharmaCompass also assists you with knowing the Prazepam API Price utilized in the formulation of products. Prazepam API Price is not always fixed or binding as the Prazepam Price is obtained through a variety of data sources. The Prazepam Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Lysanxia manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lysanxia, including repackagers and relabelers. The FDA regulates Lysanxia manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lysanxia API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Lysanxia manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Lysanxia supplier is an individual or a company that provides Lysanxia active pharmaceutical ingredient (API) or Lysanxia finished formulations upon request. The Lysanxia suppliers may include Lysanxia API manufacturers, exporters, distributors and traders.
click here to find a list of Lysanxia suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Lysanxia DMF (Drug Master File) is a document detailing the whole manufacturing process of Lysanxia active pharmaceutical ingredient (API) in detail. Different forms of Lysanxia DMFs exist exist since differing nations have different regulations, such as Lysanxia USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Lysanxia DMF submitted to regulatory agencies in the US is known as a USDMF. Lysanxia USDMF includes data on Lysanxia's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Lysanxia USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Lysanxia suppliers with USDMF on PharmaCompass.
A Lysanxia written confirmation (Lysanxia WC) is an official document issued by a regulatory agency to a Lysanxia manufacturer, verifying that the manufacturing facility of a Lysanxia active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Lysanxia APIs or Lysanxia finished pharmaceutical products to another nation, regulatory agencies frequently require a Lysanxia WC (written confirmation) as part of the regulatory process.
click here to find a list of Lysanxia suppliers with Written Confirmation (WC) on PharmaCompass.
Lysanxia Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lysanxia GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lysanxia GMP manufacturer or Lysanxia GMP API supplier for your needs.
A Lysanxia CoA (Certificate of Analysis) is a formal document that attests to Lysanxia's compliance with Lysanxia specifications and serves as a tool for batch-level quality control.
Lysanxia CoA mostly includes findings from lab analyses of a specific batch. For each Lysanxia CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lysanxia may be tested according to a variety of international standards, such as European Pharmacopoeia (Lysanxia EP), Lysanxia JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lysanxia USP).